Skip to main content
SpringerLink
Log in

Cessation of smoking in COPD: a reality check

  • CE - LETTER TO THE EDITOR
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Tashkin DP (2021) Smoking cessation in COPD: confronting the challenge. Intern Emerg Med. https://doi.org/10.1007/s11739-021-02710-2 (Epub ahead of print. PMID: 33765300)

    Article  PubMed  PubMed Central  Google Scholar 

  2. Polosa R, Morjaria JB, Prosperini U, Busà B, Pennisi A, Gussoni G, Rust S, Maglia M, Caponnetto P (2021) Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Intern Emerg Med. https://doi.org/10.1007/s11739-021-02674-3 (Epub ahead of print. PMID: 33754228)

    Article  PubMed  PubMed Central  Google Scholar 

  3. McNeill A, Brose LS, Calder R, Bauld L, Robson D (2018) Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. https://www.gov.uk/government/publications/e-cigarettes-and-heated-tobacco-products-evidence-review

  4. National Academies of Sciences, Engineering, and Medicine (NASEM) (2018) Public health consequences of e-cigarettes. The National Academies Press

    Google Scholar 

  5. Polosa R, Morjaria JB, Prosperini U, Busà B, Pennisi A, Malerba M, Maglia M, Caponnetto P (2020) COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. Ther Adv Chronic Dis 10(11):2040622320961617. https://doi.org/10.1177/2040622320961617 (PMID:33101622;PMCID:PMC7549158)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

    Riccardo Polosa

  2. Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital “Policlinico - V. Emanuele”, University of Catania, Catania, Italy

    Riccardo Polosa

  3. Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Università di Catania, Catania, Italy

    Riccardo Polosa

  4. UOC Medicina Interna e Urgenza, AOU “Policlinico - V. Emanuele – San Marco”, via S. Sofia, 78 - Ed. 4, p. 2, stanza 78, 95100, Catania, Italy

    Riccardo Polosa

Authors
  1. Riccardo Polosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Polosa.

Ethics declarations

Conflict of interest

RP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no-profit organizations. RP has also received grants from European Commission initiatives (U-BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Network (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics,ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigatorinitiated research projects on harm reduction. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4).

Informed consent

For this type of study informed consent is not required.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polosa, R. Cessation of smoking in COPD: a reality check. Intern Emerg Med 16, 2029–2030 (2021). https://doi.org/10.1007/s11739-021-02740-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-021-02740-w

Search

Navigation